{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:28:51Z","timestamp":1792510131089,"version":"4.5.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>CDK4\/6 inhibitors (CDK4\/6i) are cornerstone therapies in Hormone Receptor Positive (HR+)\/Human Epidermal Growth Factor Receptor 2 Negative (HER2\u2212) Breast Cancer (BC) and emerging evidence suggests that they may influence immune function, potentially enhancing antitumor immunity but also triggering autoimmune reactions. This study aims to investigate the prevalence of autoimmune diseases (AD) in patients with HR+\/HER2\u2212 BC to identify potential predictive biomarkers and to assess the impact of AD on disease progression.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods<\/jats:title>\n                  <jats:p>This retrospective-prospective cohort study included consecutive HR+\/HER2- BC patients treated with CDK4\/6i at Humanitas Research Hospital. Clinical-pathological features, treatment data, AD occurrence, and blood test values were collected. Descriptive statistics were used to determine AD prevalence, Kaplan-Meier method to estimate progression-free survival (PFS), and log-rank test to compare survival curves.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>352 patients (median age: 54 years) were enrolled, of which 87.2% had metastatic disease and received palbociclib, abemaciclib, or ribociclib (45.2%, 31.0%, and 23.9%, respectively). 12.8% of patients had early BC and received abemaciclib. ADs were identified in 49 patients: most had pre-existing conditions (38 stable and 4 flaring during treatment) while 7 developed new-onset ADs. The most frequent AD were Hashimoto thyroiditis, vitiligo, and rheumatoid arthritis. In the metastatic setting, the median PFS was significantly longer in patients with AD compared to those without (P\u2005=\u2005.0013), with patients with flaring or new-onset AD showing a better PFS (P\u2005=\u2005.0015). No significant predictive biomarkers for AD evolution were found.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>CDK4\/6i therapy is feasible in patients with pre-existing AD. Interestingly, the onset or flaring of AD during treatment is associated with improved PFS, suggesting a potential immune activation induced by CDK4\/6i. However, further robust and prospective studies are required to validate these findings and explore the underlying mechanisms.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf123","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T14:28:42Z","timestamp":1749738522000},"source":"Crossref","is-referenced-by-count":6,"title":["Pre-existing and emerging immune-mediated diseases in patients with breast cancer undergoing cyclin-dependent kinases 4\/6 inhibitors and endocrine therapy"],"prefix":"10.1093","volume":"30","author":[{"given":"Flavia","family":"Jacobs","sequence":"first","affiliation":[{"name":"Humanitas Cancer Center, IRCCS Humanitas Research Hospital , Rozzano, MI ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Gaudio","sequence":"additional","affiliation":[{"name":"Humanitas Cancer Center, IRCCS Humanitas Research Hospital , Rozzano, MI ,","place":["Italy"]},{"name":"Department of Biomedical Sciences, Humanitas University , Pieve Emanuele, MI ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Andreottola","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , Pieve Emanuele, MI ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Borroni","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , Pieve Emanuele, MI ,","place":["Italy"]},{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital , Rozzano, MI ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Benvenuti","sequence":"additional","affiliation":[{"name":"Humanitas Cancer Center, IRCCS Humanitas Research Hospital , Rozzano, MI ,","place":["Italy"]},{"name":"Department of Biomedical Sciences, Humanitas University , Pieve Emanuele, MI ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Saltalamacchia","sequence":"additional","affiliation":[{"name":"Humanitas Cancer Center, IRCCS Humanitas Research Hospital , Rozzano, MI ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Gerosa","sequence":"additional","affiliation":[{"name":"Humanitas Cancer Center, IRCCS Humanitas Research Hospital , Rozzano, MI ,","place":["Italy"]},{"name":"Department of Biomedical Sciences, Humanitas University , Pieve Emanuele, MI ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Canzian","sequence":"additional","affiliation":[{"name":"Humanitas Cancer Center, IRCCS Humanitas Research Hospital , Rozzano, MI ,","place":["Italy"]},{"name":"Department of Biomedical Sciences, Humanitas University , Pieve Emanuele, MI ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Tiberio","sequence":"additional","affiliation":[{"name":"Humanitas Cancer Center, IRCCS Humanitas Research Hospital , Rozzano, MI ,","place":["Italy"]},{"name":"Department of Biomedical Sciences, Humanitas University , Pieve Emanuele, MI ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalba","family":"Torrisi","sequence":"additional","affiliation":[{"name":"Humanitas Cancer Center, IRCCS Humanitas Research Hospital , Rozzano, MI ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Masci","sequence":"additional","affiliation":[{"name":"Humanitas Cancer Center, IRCCS Humanitas Research Hospital , Rozzano, MI ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Miggiano","sequence":"additional","affiliation":[{"name":"Humanitas Cancer Center, IRCCS Humanitas Research Hospital , Rozzano, MI ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1374-1831","authenticated-orcid":false,"given":"Alberto","family":"Zambelli","sequence":"additional","affiliation":[{"name":"Humanitas Cancer Center, IRCCS Humanitas Research Hospital , Rozzano, MI ,","place":["Italy"]},{"name":"Department of Biomedical Sciences, Humanitas University , Pieve Emanuele, MI ,","place":["Italy"]},{"name":"Department of Medical Oncology, ASST Papa Giovanni XXIII , 24127 Bergamo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[{"name":"Humanitas Cancer Center, IRCCS Humanitas Research Hospital , Rozzano, MI ,","place":["Italy"]},{"name":"Department of Biomedical Sciences, Humanitas University , Pieve Emanuele, MI ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3202-1933","authenticated-orcid":false,"given":"Rita","family":"De Sanctis","sequence":"additional","affiliation":[{"name":"Humanitas Cancer Center, IRCCS Humanitas Research Hospital , Rozzano, MI ,","place":["Italy"]},{"name":"Department of Biomedical Sciences, Humanitas University , Pieve Emanuele, MI ,","place":["Italy"]},{"name":"Department of Medical Oncology, ASST Papa Giovanni XXIII , 24127 Bergamo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"issue":"3","key":"2025061210283070700_CIT0001","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin."},{"issue":"12","key":"2025061210283070700_CIT0002","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol."},{"issue":"20","key":"2025061210283070700_CIT0003","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and Letrozole in Advanced Breast Cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med."},{"issue":"32","key":"2025061210283070700_CIT0004","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol."},{"issue":"18","key":"2025061210283070700_CIT0005","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med."},{"issue":"5","key":"2025061210283070700_CIT0006","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1158\/1078-0432.CCR-21-3032","article-title":"Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+\/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial","volume":"28","author":"Lu","year":"2022","journal-title":"Clin Cancer Res."},{"issue":"7","key":"2025061210283070700_CIT0007","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol"},{"issue":"24","key":"2025061210283070700_CIT0008","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3","volume":"36","author":"Slamon","year":"2018","journal-title":"J Clin Oncol"},{"issue":"25","key":"2025061210283070700_CIT0009","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2\u2212 advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025061210283070700_CIT0010","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","article-title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"issue":"8","key":"2025061210283070700_CIT0011","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.annonc.2024.04.013","article-title":"Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3","volume":"35","author":"Goetz","year":"2024","journal-title":"Ann Oncol"},{"issue":"12","key":"2025061210283070700_CIT0012","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.annonc.2024.08.2345","article-title":"Unlocking methodological insights on oncology efficacy endpoints: from statistical to clinical and vice versa. letter to the editor regarding \u2018abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2\u2212 advanced breast cancer: Final overall survival results of MONARCH 3\u2019","volume":"35","author":"De Sanctis","year":"2024","journal-title":"Ann Oncol"},{"issue":"9","key":"2025061210283070700_CIT0013","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1200\/JCO.23.00137","article-title":"Overall survival with palbociclib plus letrozole in advanced breast cancer","volume":"42","author":"Slamon","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025061210283070700_CIT0014","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Johnston","year":"2023","journal-title":"Lancet Oncol"},{"key":"2025061210283070700_CIT0015","doi-asserted-by":"publisher","first-page":"17588359231178125","DOI":"10.1177\/17588359231178125","article-title":"Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+\/HER2- early breast cancer","volume":"15","author":"Slamon","year":"2023","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"2025061210283070700_CIT0016","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40265-020-01461-2","article-title":"Inhibiting CDK4\/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences","volume":"81","author":"Braal","year":"2021","journal-title":"Drugs"},{"key":"2025061210283070700_CIT0017","doi-asserted-by":"publisher","first-page":"693104","DOI":"10.3389\/fonc.2021.693104","article-title":"Clinical and pharmacologic differences of CDK4\/6 inhibitors in breast cancer","volume":"11","author":"George","year":"2021","journal-title":"Front Oncol"},{"issue":"3","key":"2025061210283070700_CIT0018","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrc2602","article-title":"Cell cycle, CDKs and cancer: a changing paradigm","volume":"9","author":"Malumbres","year":"2009","journal-title":"Nat Rev Cancer."},{"key":"2025061210283070700_CIT0019","doi-asserted-by":"publisher","first-page":"10401","DOI":"10.1016\/j.ebiom.2022.104010","article-title":"Immune effects of CDK4\/6 inhibitors in patients with HR+\/HER2- metastatic breast cancer: relief from immunosuppression is associated with clinical response","volume":"79","author":"Scirocchi","year":"2022","journal-title":"EBioMedicine"},{"issue":"Supplement 4","key":"2025061210283070700_CIT0020","doi-asserted-by":"publisher","first-page":"103247","DOI":"10.1016\/j.esmoop.2024.103247","article-title":"225P Impact of cyclin inhibitors (CDK4\/6i) on immune cell populations in first-line treated metastatic breast cancer (mBC) patients","volume":"9","author":"S\u00e1nchez-Le\u00f3n","year":"2024","journal-title":"ESMO Open."},{"issue":"9","key":"2025061210283070700_CIT0021","doi-asserted-by":"publisher","first-page":"e007126","DOI":"10.1136\/jitc-2023-007126","article-title":"Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)","volume":"11","author":"Masuda","year":"2023","journal-title":"J ImmunoTher Cancer"},{"key":"2025061210283070700_CIT0022","doi-asserted-by":"publisher","first-page":"793234","DOI":"10.3389\/fimmu.2022.793234","article-title":"Autoimmunity and cancer-two sides of the same coin","volume":"13","author":"Sakowska","year":"2022","journal-title":"Front Immunol"},{"issue":"10391","key":"2025061210283070700_CIT0023","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1016\/S0140-6736(23)00457-9","article-title":"Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK","volume":"401","author":"Conrad","year":"2023","journal-title":"Lancet"},{"issue":"14","key":"2025061210283070700_CIT0024","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.3390\/cancers15143658","article-title":"Cyclin-dependent kinase 4\/6 inhibitors and dermatologic adverse events: results from the EADV Task Force \u201cDermatology for Cancer Patients\u201d International Study","volume":"15","author":"Sollena","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025061210283070700_CIT0025","doi-asserted-by":"publisher","first-page":"1020709","DOI":"10.3389\/fpubh.2022.1020709","article-title":"Global prevalence and epidemiological trends of Hashimoto\u2019s thyroiditis in adults: a systematic review and meta-analysis","volume":"10","author":"Hu","year":"2022","journal-title":"Front Public Health."},{"issue":"4","key":"2025061210283070700_CIT0026","doi-asserted-by":"publisher","first-page":"e248782","DOI":"10.1136\/bcr-2022-248782","article-title":"Ribociclib-induced extensive vitiligo-like lesions: possible pathomechanisms with clinical, dermoscopic and histological correlation","volume":"15","author":"Anjaneyan","year":"2022","journal-title":"BMJ Case Rep"},{"key":"2025061210283070700_CIT0027","doi-asserted-by":"publisher","first-page":"1611115","DOI":"10.3389\/pore.2023.1611115","article-title":"Vitiligo-like lesions induced by cyclin-dependent kinase 4\/6 inhibitor Palbociclib: a case report and literature review","volume":"29","author":"Gao","year":"2023","journal-title":"Pathol Oncol Res"},{"issue":"1","key":"2025061210283070700_CIT0028","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s10549-020-05914-w","article-title":"Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors","volume":"185","author":"Sollena","year":"2021","journal-title":"Breast Cancer Res Treat."},{"issue":"3","key":"2025061210283070700_CIT0029","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.1365-4632.2004.01948.x","article-title":"Late onset vitiligo: a study of 182 patients","volume":"44","author":"Dogra","year":"2005","journal-title":"Int J Dermatol."},{"issue":"2","key":"2025061210283070700_CIT0030","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1080\/24725625.2021.1886400","article-title":"Amelioration of rheumatoid arthritis in a breast cancer patient treated with palbociclib: a case report","volume":"5","author":"Murakami","year":"2021","journal-title":"Mod Rheumatol Case Rep"},{"key":"2025061210283070700_CIT0031","doi-asserted-by":"publisher","first-page":"1067264","DOI":"10.3389\/fonc.2023.1067264","article-title":"Case report: Vitiligo-like toxicity due to ribociclib during first-line treatment of metastatic breast cancer: two cases of premature interruption of therapy and exceptional response","volume":"13","author":"Pasqualoni","year":"2023","journal-title":"Front Oncol"},{"issue":"1","key":"2025061210283070700_CIT0032","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"7","key":"2025061210283070700_CIT0033","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J Clin Oncol"},{"issue":"12","key":"2025061210283070700_CIT0034","doi-asserted-by":"publisher","first-page":"13086","DOI":"10.1002\/cam4.5989","article-title":"Survival in elderly patients with breast cancer with and without autoimmune disease","volume":"12","author":"Dedousis","year":"2023","journal-title":"Cancer Med"},{"issue":"1","key":"2025061210283070700_CIT0035","doi-asserted-by":"publisher","first-page":"9869","DOI":"10.1038\/s41598-024-60101-x","article-title":"Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4\/6 inhibitor efficacy in advanced breast cancer","volume":"14","author":"Nakamoto","year":"2024","journal-title":"Sci Rep."},{"issue":"3","key":"2025061210283070700_CIT0036","doi-asserted-by":"publisher","first-page":"e319","DOI":"10.1093\/oncolo\/oyad301","article-title":"Association of neutrophil-to-lymphocyte ratio and absolute lymphocyte count with clinical outcomes in advanced breast cancer in the MONARCH 2 Trial","volume":"29","author":"Tokunaga","year":"2024","journal-title":"Oncologist"},{"key":"2025061210283070700_CIT0037","doi-asserted-by":"publisher","first-page":"1105587","DOI":"10.3389\/fonc.2022.1105587","article-title":"Pretreatment neutrophil to lymphocyte ratio as prognostic factor in metastatic breast cancer treated with cyclin dependent kinase 4\/6 inhibitors","volume":"12","author":"Rottier","year":"2023","journal-title":"Front Oncol."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/6\/oyaf123\/63478002\/oyaf123.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/6\/oyaf123\/63478002\/oyaf123.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T14:28:42Z","timestamp":1749738522000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf123\/8160960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf123","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,6]]},"article-number":"oyaf123"}}